Study Creates Lifespan Reference Charts for Human Brain White Matter
Researchers processed 35,120 brain scans to map typical white matter development and decline from birth to age 100. The charts provide a benchmark for identifying deviations linked to neurological and psychiatric disorders.
sciencealert.comA new set of reference charts tracks the growth, maturation, and age-related decline of white matter across the human lifespan. White matter forms the main communication pathways between brain regions, and disruptions in these pathways are associated with several neurological, psychiatric, and developmental disorders.
Researchers compiled and standardized 35,120 brain scans from multiple global studies. The resulting charts show typical patterns from birth through age 100, establishing a baseline for healthy brain development and aging. The charts allow researchers and clinicians to compare individual brain scans against normative data.
This comparison can help quantify how a person's white matter structure deviates from expected patterns.
The study provides open-access charts for use by the scientific and clinical communities. Researchers can evaluate new patient data or research scans against these baselines to support future studies. The work addresses the absence of a standard reference for white matter measurements, similar to existing growth charts used for physical development and grey matter volume.
Key Facts
Potential Impact
- 01
Researchers can evaluate new data against the published normative baselines.
- 02
Clinicians may use the charts to compare patient scans against typical development patterns.
Transparency Panel
Related Stories
NprWHO Director Visits Congo as Ebola Outbreak Spreads
The head of the World Health Organization arrived in Kinshasa to support efforts against a rare Ebola strain. Health workers face equipment shortages, community distrust, and armed conflict in affected provinces.
medpagetoday.comFDA Panel Recommends XFG Variant for Fall Covid Shots
Replimune will submit an application to the FDA for the third time. Pfizer and Innovent Biologics reached a collaboration agreement valued at up to $10.5 billion.
Benzinga Publishes Article on Biotech Stocks During Pandemic Recovery
Benzinga published an article titled 'Best Biotech Stocks Right Now' that addresses the sector's position during global recovery from the pandemic. The piece notes government institutions and professional traders are focusing on biotech companies for vaccine and booster developme…